We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Prithviraj Bose

Prithviraj Bose MD

Associate Professor, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
Dr. Prithviraj Bose is an associate professor in the Department of Leukemia at the MD Anderson Cancer Center. After obtaining his medical degree from the University of Calcutta in Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose completed an internship in internal medicine at a University of Washington affiliate in Spokane, WA, and residency at the Henry Ford Hospital in Detroit, MI, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, OK. He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, VA, where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center.

At the Department of Leukemia at MDACC, which he joined in early 2015, Dr. Bose’s major clinical and research focus is on MPNs. He works closely with Dr. Srdan Verstovsek, Professor in the Department of Leukemia and chief of the section of MPNs. The two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as the pivotal trial of ruxolitinib in essential thrombocythemia.

Dr. Bose has published nearly 200 peer-reviewed journal articles, book chapters and scientific meeting abstracts. His work has appeared in The New England Journal of Medicine, Cancer Cell, Blood and Williams’ Hematology. Additionally, Dr. Bose has served as a peer-reviewer for multiple hematology and oncology journals, including The Lancet Oncology, JAMA Oncology, Blood, The Lancet Haematology, etc. In 2011, Dr. Bose was selected to participate in the American Society of Hematology’s prestigious Clinical Research Training Institute. Now a naturalized US citizen, he was granted permanent residence in the United States in 2013 in the select “outstanding researcher” (first preference) category.

Disclosures

No disclosures reported.